Catalog #CP093
RecombiMAb anti-mouse CTLA-4 (CD152)
Clone
9D9-CP093
Reactivities
Mouse
Applications
in vivo CTLA-4 neutralization
in vivo intra-tumoral regulatory T cell depletion
ELISA
in vivo intra-tumoral regulatory T cell depletion
ELISA
Isotype
Mouse IgG2c, κ
(switched from Mouse IgG2b, κ)
(switched from Mouse IgG2b, κ)
You may also be interested in:
Product Description
The 9D9-CP093 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original 9D9 antibody. The variable domain sequences are identical but the constant region sequences have been switched from mouse IgG2b to mouse IgG2c. Recombinant 9D9 that has been isotype switched to either mouse IgG2a or IgG2c has demonstrated improved Fc effector function resulting in potent depletion of intratumoral Tregs, increased activation of CD8+ T cells, increased tumor-associated high endothelial venules (TA-HEVs), and increased tumor-draining lymph node priming resulting in superior antitumor efficacy through Fc-dependent mechanisms compared to the original IgG2b antibody. Isotype switching amplified ADCC/ADCP via high-affinity binding to activating FcγRs, combining CTLA-4 blockade with Treg elimination for robust antitumor immunity. Mouse IgG2a and IgG2c are allelic variants of the same isotype, differing by strain-specific genetics, and are indistinguishable in their specificities to murine FcγR. Both mouse IgG2a and IgG2c have broader and higher-affinity interactions with activating FcγRs than mouse IgG2b. Mouse strains such as C57Bl/6, C57Bl/10, SJL, and NOD mice possess the Igh1-b allele resulting in only the expression of IgG2c. However, mouse strains such as BALB/c and Swiss Webster mice possess the Igh1-a allele which results in only the expression of IgG2a. It is important to consider matching the Ig-haplotype of the receiving mice to the isotype of the injected antibody to avoid eliciting an undesired immune response and ensure better antibody tolerance, pharmacokinetics, and efficacy. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies. The 9D9 monoclonal antibody is a commonly used surrogate for CTLA-4 checkpoint blockade studies in mouse cancer models. It reacts with mouse CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152.
Bates, Amber M et al. “Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer.” Frontiers in oncology vol. 11 645352. 15 Apr. 2021, doi:10.3389/fonc.2021.645352
Blanchard, Lucas et al. “Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.” Cell reports. Medicine vol. 6,6 (2025): 102141. doi:10.1016/j.xcrm.2025.102141
Kerr, Caroline P et al. “Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition.” bioRxiv : the preprint server for biology 2024.12.26.630430. 26 Dec. 2024, doi:10.1101/2024.12.26.630430. Preprint.
Rakhmilevich, Alexander L et al. “A combined radio-immunotherapy regimen eradicates late-stage tumors in mice.” Frontiers in immunology vol. 15 1419773. 15 Jul. 2024, doi:10.3389/fimmu.2024.1419773
Selby, Mark J et al. “Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.” Cancer immunology research vol. 1,1 (2013): 32-42. doi:10.1158/2326-6066.CIR-13-0013
Bates, Amber M et al. “Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer.” Frontiers in oncology vol. 11 645352. 15 Apr. 2021, doi:10.3389/fonc.2021.645352
Blanchard, Lucas et al. “Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.” Cell reports. Medicine vol. 6,6 (2025): 102141. doi:10.1016/j.xcrm.2025.102141
Kerr, Caroline P et al. “Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition.” bioRxiv : the preprint server for biology 2024.12.26.630430. 26 Dec. 2024, doi:10.1101/2024.12.26.630430. Preprint.
Rakhmilevich, Alexander L et al. “A combined radio-immunotherapy regimen eradicates late-stage tumors in mice.” Frontiers in immunology vol. 15 1419773. 15 Jul. 2024, doi:10.3389/fimmu.2024.1419773
Selby, Mark J et al. “Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.” Cancer immunology research vol. 1,1 (2013): 32-42. doi:10.1158/2326-6066.CIR-13-0013
Specifications
| Isotype | Mouse IgG2c, κ |
|---|---|
| Recommended Isotype Control(s) | InVivoPlus mouse IgG2c isotype control, anti-dengue virus |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Not available or unknown |
| Reported Applications |
in vivo CTLA-4 neutralization in vivo intra-tumoral regulatory T cell depletion ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |